Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Brazilian (BOVESPA) Healthcare Sector Analysis

UpdatedApr 13, 2026
DataAggregated Company Financials
Companies16
  • 7D4.8%
  • 3M0.4%
  • 1Y19.6%
  • YTD1.6%

The Healthcare industry is up 4.8% in the last week, with Rede D'Or São Luiz up 4.1%. Meanwhile, Oncoclínicas do Brasil Serviços Médicos actually underperformed within the industry, shrinking 8.1% in the last week. This takes the industry's 12 month performance to a gain of 20%. Earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the Brazilian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 13 Apr 2026R$145.5bR$154.0bR$2.9b13.4x50.9x0.9x
Wed, 11 Mar 2026R$137.4bR$154.2bR$3.2b14.5x42.9x0.9x
Fri, 06 Feb 2026R$145.5bR$152.1bR$1.8b13.3x78.8x1x
Sun, 04 Jan 2026R$143.5bR$152.1bR$1.8b12x77.8x0.9x
Tue, 02 Dec 2025R$156.2bR$152.1bR$1.9b12.8x84x1x
Thu, 30 Oct 2025R$152.2bR$149.9bR$2.5b11.5x60.9x1x
Sat, 27 Sep 2025R$152.8bR$149.9bR$2.5b11.9x61.2x1x
Mon, 25 Aug 2025R$144.3bR$144.3bR$2.5b12.1x57.9x1x
Wed, 23 Jul 2025R$131.4bR$149.5bR$2.0b11.1x64.5x0.9x
Fri, 20 Jun 2025R$142.3bR$149.5bR$2.0b11.3x69.8x1x
Sun, 18 May 2025R$143.2bR$149.6bR$2.0b10.9x70x1x
Tue, 15 Apr 2025R$121.4bR$150.7bR$2.2b10.5x55.2x0.8x
Thu, 13 Mar 2025R$113.1bR$148.1bR$4.9b10.9x23x0.8x
Sat, 08 Feb 2025R$117.2bR$146.7bR$4.7b11.4x25.1x0.8x
Mon, 06 Jan 2025R$107.7bR$146.7bR$4.7b10.6x23.1x0.7x
Wed, 04 Dec 2024R$119.7bR$146.7bR$4.7b12x25.7x0.8x
Fri, 01 Nov 2024R$139.0bR$144.9bR$4.4b11.4x31.6x1x
Sun, 29 Sep 2024R$148.1bR$144.9bR$4.4b11.5x33.6x1x
Tue, 27 Aug 2024R$160.6bR$144.9bR$4.4b11.8x36.5x1.1x
Thu, 25 Jul 2024R$140.0bR$143.3bR$4.2b11.3x33.6x1x
Sat, 22 Jun 2024R$134.2bR$142.9bR$4.2b11.5x32.1x0.9x
Mon, 20 May 2024R$154.4bR$142.9bR$4.2b12x37x1.1x
Wed, 17 Apr 2024R$132.6bR$140.0bR$3.2b11.6x41.8x0.9x
Fri, 15 Mar 2024R$145.9bR$133.3bR$2.6b14.4x55.3x1.1x
Sun, 11 Feb 2024R$148.3bR$132.9bR$2.7b17x54.7x1.1x
Tue, 09 Jan 2024R$164.7bR$135.0bR$2.9b20.4x57.1x1.2x
Thu, 07 Dec 2023R$162.3bR$135.0bR$2.9b20.2x56.3x1.2x
Sat, 04 Nov 2023R$151.1bR$126.2bR$2.8b18x54.4x1.2x
Mon, 02 Oct 2023R$163.7bR$126.1bR$2.7b19.1x59.6x1.3x
Wed, 30 Aug 2023R$174.6bR$126.1bR$2.7b20.6x63.5x1.4x
Fri, 28 Jul 2023R$197.0bR$116.7bR$2.8b16.5x69.9x1.7x
Sun, 25 Jun 2023R$183.3bR$116.7bR$2.8b16.3x65x1.6x
Tue, 23 May 2023R$161.2bR$110.8bR$2.8b14.9x58.5x1.5x
Thu, 20 Apr 2023R$128.4bR$106.3bR$3.3b14.2x38.6x1.2x
Price to Earnings Ratio

38.6x


Total Market Cap: R$128.4bTotal Earnings: R$3.3bTotal Revenue: R$106.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Brazilian Healthcare Sector Price to Earnings3Y Average 51.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Brazilian Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.0x which is lower than its 3-year average PE of 51.2x.
  • The 3-year average PS ratio of 1.1x is higher than the industry's current PS ratio of 0.94x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.1% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Brazilian Healthcare sector?

BR Market4.38%
Healthcare4.80%
Healthcare Services5.20%
Biotech3.78%
Pharma2.06%
Medical Equipment0.85%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry even though it's trading below its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 21.2%, which is higher than its past year's earnings growth of 5.9% per year.
  • Investors are most pessimistic about the Pharma industry, which is trading below its 3-year average of 13.7x.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 23% over the next 5 years.
  • This is roughly in line with its past earnings growth rate.
  • In contrast, the Biotech industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RDOR3 Rede D'Or São LuizR$41.404.2%
+R$3.7b		39.6%PE19.5x
HAPV3 Hapvida Participações e InvestimentosR$13.2524.1%
+R$1.2b		-60.7%PS0.2x
ODPV3 OdontoprevR$15.4812.7%
+R$953.9m		47.4%PE14.5x
FLRY3 FleuryR$16.926.3%
+R$545.0m		39.5%PE15x
HYPE3 HyperaR$23.392.3%
+R$329.1m		18.6%PE12.4x

Latest News

ONCO3
R$1.24
Oncoclínicas do Brasil Serviços Médicos
7D
-13.3%
1Y
-77.4%
RDOR3
R$41.40
Rede D'Or São Luiz
7D
4.2%
1Y
39.6%

RDOR3: Stable P/E Assumptions And Equity Interest Will Support Bullish Repricing

Analysts maintained their R$50.44 price target for Rede D'Or São Luiz, citing stable assumptions for the discount rate, revenue growth, profit margin and future P/E as the basis for their view. What's in the News A board meeting is scheduled for March 23, 2026, to consider the distribution of interest on equity.
FLRY3
R$16.92
Fleury
7D
6.3%
1Y
39.5%

FLRY3: Special Meeting Will Highlight Overvaluation Risks Despite Minor Assumption Tweaks

Analysts have kept Fleury's R$14.40 price target effectively unchanged, citing only slight adjustments to revenue growth, profit margin and forward P/E assumptions that leave their overall view largely intact. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, to be held exclusively in Brazil.
HAPV3
R$13.25
Hapvida Participações e Investimentos
7D
24.1%
1Y
-60.7%

HAPV3: Downgrade And Margin Concerns Will Constrain Future Upside Potential

Analysts have cut their price target on Hapvida Participações e Investimentos from R$15.00 to R$7.00, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E following recent research, including a downgrade from a major global bank. Analyst Commentary Recent sell side research around Hapvida Participações e Investimentos points to a more cautious tone, with the reduced price target to R$7.00 framed as a reassessment of risk rather than a simple valuation tweak.
BLAU3
R$11.34
Blau Farmacêutica
7D
6.1%
1Y
15.3%

BLAU3: U.S. Subsidiary Investment And Stable Fair Value Will Shape Returns

Analysts have adjusted their price target for Blau Farmacêutica to R$11.00, with updated assumptions that reflect a slightly different discount rate, higher revenue expectations, a lower profit margin outlook, and a higher future P/E multiple. What's in the News Board meeting scheduled for Feb 04, 2026, at 13:00 UTC to consider and approve an investment in the company subsidiary in the United States, and to authorize the Board of Executive Officers to execute this plan (company filing).
HYPE3
R$23.39
Hypera
7D
2.3%
1Y
18.6%
BIOM3
R$7.35
Biomm
7D
-2.1%
1Y
-22.9%
DASA3
R$3.22
Diagnósticos da América
7D
4.5%
1Y
76.9%
ODPV3
R$15.48
Odontoprev
7D
12.7%
1Y
47.4%

ODPV3: Share Merger Steps And Steady Assumptions Will Shape Balanced Outlook

Analysts have kept their R$14.23 price target for Odontoprev unchanged, citing only slight tweaks to revenue growth, profit margin and forward P/E assumptions that broadly offset one another in their models. What's in the News A board meeting is scheduled for Mar 06, 2026, at 20:00 Coordinated Universal Time to decide on the execution of the First Amendment to the Protocol and Justification for the Merger of Shares issued by Bradesco Gestão de Saúde S.A. into Odontoprev S.A. (Key Developments) At the same board meeting, directors plan to review the appraisal report of Bradesco Gestão de Saúde S.A.'s net equity at market prices to determine the amount of Odontoprev's capital increase resulting from the proposed share merger (Key Developments) The agenda also includes a resolution on the capital increase and the related amendment to Article 6 of Odontoprev's bylaws, linked to the Merger of Shares with Bradesco Gestão de Saúde S.A. (Key Developments) Board members intend to register updated appraisal reports for the net equity of both Odontoprev and Bradesco Gestão de Saúde S.A. to compare the replacement ratio for the Merger of Shares, in accordance with Article 264 of the Brazilian Corporations Law (Key Developments) A Special/Extraordinary Shareholders Meeting is called for Apr 06, 2026, to be held exclusively on alfm easy voting, Brazil, where investors can expect decisions related to the matters prepared at the March board meeting (Key Developments) Valuation Changes Fair Value: R$14.23 remains unchanged, indicating no adjustment to the overall valuation output in the model.
AALR3
R$3.60
Alliança Saúde e Participações
7D
-7.7%
1Y
-29.5%
QUAL3
R$2.24
Qualicorp Consultoria e Corretora de Seguros
7D
10.3%
1Y
16.1%